These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2820626)

  • 1. Rapid measurement of total and active renin: plasma concentrations during acute and sustained converting enzyme inhibition with CGS 14824A.
    Nussberger J; de Gasparo M; Juillerat L; Guyenne TT; Mooser V; Waeber B; Brunner HR
    Clin Exp Hypertens A; 1987; 9(8-9):1353-66. PubMed ID: 2820626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A.
    Waeber G; Fasanella d'Amore T; Nussberger J; Waeber B; Brunner HR
    Eur J Clin Pharmacol; 1987; 31(6):643-6. PubMed ID: 3030765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers.
    Schaller MD; Nussberger J; Waeber B; Bussien JP; Turini GA; Brunner H; Brunner HR
    Eur J Clin Pharmacol; 1985; 28(3):267-72. PubMed ID: 2988972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.
    Waeber G; Burnier M; Porchet M; Nussberger J; Waeber B; Brunner HR
    Eur J Clin Pharmacol; 1989; 36(6):587-91. PubMed ID: 2550244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine.
    Bellet M; Sassano P; Guyenne T; Corvol P; Menard J
    Br J Clin Pharmacol; 1987 Oct; 24(4):465-72. PubMed ID: 3689627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of chronic inhibition of renin and converting enzyme in the marmoset.
    Wood JM; Jobber RA; Baum HP; Hofbauer KG
    Clin Exp Hypertens A; 1987; 9(2-3):337-43. PubMed ID: 3038392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.
    Squire IB; MacFayden RJ; Reid JL; Devlin A; Lees KR
    J Cardiovasc Pharmacol; 1996 May; 27(5):657-66. PubMed ID: 8859935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of eight-day converting enzyme inhibition on ambulatory blood pressure recordings in normotensive volunteers.
    Bidiville J; Porchet M; Bussien JP; Nussberger J; Waeber B; Brunner HR
    Arch Int Pharmacodyn Ther; 1987 Jul; 288(1):109-19. PubMed ID: 2959228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers.
    Shepherd AN; Campbell BC; Reid JL
    J Cardiovasc Pharmacol; 1982; 4(3):381-7. PubMed ID: 6177933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with perindopril in normal volunteers.
    Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR
    Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():35-41. PubMed ID: 2549899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antirenin immunization versus angiotensin converting enzyme inhibition in rats.
    Lo M; Julien C; Michel JB; Vincent M; Cerutti C; Gomez-Sanchez CE; Sassard J
    Hypertension; 1990 Jul; 16(1):80-8. PubMed ID: 2194942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.
    Rousso P; Buclin T; Nussberger J; Décosterd LA; La Roche SD; Brunner-Ferber F; Brunner HR; Biollaz J
    J Hypertens; 1999 Mar; 17(3):427-37. PubMed ID: 10100082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potent converting enzyme inhibitor CGS 13928C. Drug profile in normal volunteers.
    Schaller MD; Brunner DB; Nussberger J; Turini GA; Sen SB; Chen D; Waeber B; Brunner HR
    Eur J Clin Pharmacol; 1984; 26(4):419-24. PubMed ID: 6329767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.
    MacFadyen RJ; Lees KR; Reid JL
    Br Heart J; 1991 Sep; 66(3):206-11. PubMed ID: 1657084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial and endocrine effects of a combination of an angiotensin converting enzyme inhibitor and a vasodilator in normotensive healthy volunteers.
    Brunel P; Guyene TT; Howald H; Ménard J
    J Cardiovasc Pharmacol; 1991 Aug; 18(2):175-81. PubMed ID: 1717776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CGS 13945: a new orally active angiotensin-converting enzyme inhibitor in normal volunteers.
    Jacot des Combes B; Turini GA; Brunner HR; Porchet M; Chen DS; Sen S
    J Cardiovasc Pharmacol; 1983; 5(4):511-6. PubMed ID: 6193344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs.
    Ames MK; Atkins CE; Lee S; Lantis AC; zumBrunnen JR
    Am J Vet Res; 2015 Dec; 76(12):1041-50. PubMed ID: 26618728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.